On 13 May 2026, a global consensus published in The Lancet changed the name of polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS), and the reason is medical rather than cosmetic: the old name pointed attention at "cysts" on the ovary that are not pathological cysts at all, and pointed it away from the hormonal and metabolic disorder that runs through the whole body. The condition affects roughly 170 million women worldwide — about one in eight, according to Monash University — and is still diagnosed late or missed entirely in a large share of cases. This article covers what actually changed, why an ultrasound neither confirms nor rules the condition out, which commonly requested lab test the international guideline says adds little while the one that matters most gets forgotten, and what the newest evidence says about food, movement and medication.
🔎 This article is educational only and is not a substitute for your own doctor. It is not intended to diagnose your case or to prescribe treatment for it.
What changed in May 2026, and why should a name matter to you?
Renaming a condition is not a linguistic luxury. The name is the first thing a patient hears, the first thing a clinician pictures, and the thing that quietly steers research funding and diagnosis. Reaching the new one took fourteen years of international work: more than 22,000 survey responses, 56 patient and professional organisations, and international workshops with structured discussion and anonymous voting — co-led by Professor Helena Teede of Monash University and Professor Terhi Piltonen of Oulu University, in partnership with the Androgen Excess and PCOS Society and patient organisations.
The finding that forced the change, in Monash's own words, is that the old name "reduced a complex, long term hormonal or endocrine disorder to a misunderstanding about 'cysts' and a focus on ovaries", and that this "contributed to missed diagnoses and inadequate treatment". The new name unpacks that into three words that describe the condition as it is: polyendocrine, because more than one hormonal system is involved; metabolic, because disordered handling of sugar and energy is part of the picture rather than a side complication; and ovarian, because the ovary is one of the affected organs — one of them, not all of them.
Equally important is what did not change. The diagnostic criteria are unchanged, and so is the treatment plan. The transition runs over roughly three years and completes with the 2028 update of the international guideline, so you will keep seeing "PCOS" written on your medical file and your insurance paperwork for some time yet. If you already have a diagnosis, no immediate action is required of you today. The one practical gain — and it is a large one — is that the name now reminds everyone involved that your care has to include your metabolism, not just your menstrual cycle.
Are they really cysts? And why isn't the ultrasound enough?
This is where the most common misunderstanding lives. What shows on the ultrasound is not a set of pathological cysts. They are small follicles arrested at an early stage of maturation because ovulation did not complete. Cleveland Clinic describes them as small fluid-filled sacs containing immature eggs, and adds plainly that you do not need to have cysts on your ovaries to have the condition at all. Monash's statement accompanying the new name was blunter still: there is in fact no increase in abnormal cysts on the ovary.
When do you not need an ultrasound in the first place?
Diagnosis has for years rested on a two-of-three rule, after other causes have been excluded: irregular or absent cycles; signs of excess androgen (clinical, such as unwanted hair growth and acne, or biochemical); and polycystic ovarian morphology. The part most people miss is that the international guideline states in recommendation 1.4.9 that "in patients with irregular menstrual cycles and hyperandrogenism, an ovarian ultrasound is not necessary for PCOS diagnosis". Where the first two criteria are both present, the scan is a redundant step.
Two practical conclusions follow, and both are worth keeping: a normal ultrasound does not rule the condition out if your cycles are irregular and androgen signs are present, and an ultrasound showing multiple follicles does not on its own confirm it, because that appearance occurs in perfectly healthy women too. The scan is one piece of information inside an assessment, not a verdict.
What about the AMH blood test?
The guideline added a modern alternative: serum anti-Müllerian hormone (AMH) can be used to define polycystic ovarian morphology in adults instead of ultrasound (recommendation 1.5.1), with two clear conditions attached. AMH should not be used as a single test to diagnose the condition (1.5.3), and the two tests should not both be performed — ultrasound and AMH — specifically "to limit over-diagnosis" (1.5.5). It is a substitute, not an extra box to tick.
Adolescents: the eight-year rule
In adolescents specifically, polycystic ovarian morphology is common as part of normal maturation, which is why it is not relied on at that stage. Recommendation 1.1.4 states that an adolescent who has features of the condition but does not meet diagnostic criteria may be considered at "increased risk", with reassessment advised at or before full reproductive maturity, eight years post-menarche. Practically: no rushed label, and no dismissal either — follow-up.
The test that is over-ordered, and the one that gets forgotten
If one section of this article is worth clipping and keeping, it is this one.
Why isn't an insulin test recommended in routine care?
Many women go to the lab asking for a fasting insulin level or one of the insulin-resistance indices calculated from it. The guideline's position is precise and two-sided, in recommendation 3.1.10: "Insulin resistance is a pathophysiological factor in PCOS; however, clinically available insulin assays are of limited clinical relevance and should not be used in routine care." Read it carefully — the sentence does not deny insulin resistance, it affirms it. What it rejects is the available laboratory measurement of it, which is not standardised and does not change the treatment decision. The mechanism is real; the assay is weak. (If you want the mechanism itself in depth, we have a separate article on insulin resistance: signs, causes and how to reverse it.)
So what is the right test, and how often?
The test the guideline explicitly recommends is an assessment of glycaemic status, with three specific points:
- For everyone, at diagnosis: "Glycaemic status should be assessed at diagnosis in all adults and adolescents with PCOS" (recommendation 1.9.2).
- The most accurate test is the 75-g oral glucose tolerance test (OGTT), recommended "as the most accurate test to assess glycaemic status in PCOS, regardless of BMI" (recommendation 1.9.9).
- And it should be repeated every one to three years, based on individual additional risk factors for diabetes (recommendation 1.9.3).
Those three words — "regardless of BMI" — carry the whole section. Many lean or normal-weight women are steered away from this test because they do not look like a metabolic risk, while the guideline says precisely the opposite. If you have a diagnosis and have never had your glycaemic status assessed, that is an entirely reasonable question to put to your doctor at the next visit. For what the results mean and the stages behind them, see our article on prediabetes: signs, diagnosis and how to reverse it.
Why is it called "metabolic"? What lies beyond the ovary?
This is exactly what the new name encodes: the condition does not end at periods and fertility. The international guideline asks clinicians to follow several fronts, and each is a written recommendation rather than a matter of opinion.
Heart and blood vessels: the numbers, with their brakes
The guideline states that women with the condition "should be considered at increased risk of cardiovascular disease" (1.8.1), that "all women with PCOS should be assessed for cardiovascular disease risk factors" (1.8.2), and that blood pressure should be measured annually and when planning pregnancy (1.8.4). A systematic review and meta-analysis published in the Journal of the American Heart Association in 2024 — twenty studies covering 1.06 million women, of whom 369,317 had the condition — found a pooled odds ratio of 1.68 (95% CI, 1.26–2.23) for composite cardiovascular disease, 2.50 (1.43–4.38) for myocardial infarction, 1.71 (1.20–2.44) for stroke, and 1.48 (1.07–2.05) for ischaemic heart disease.
Because honesty is part of the usefulness, here are the two brakes. In the same analysis, cardiovascular mortality did not reach statistical significance — 1.19 with a confidence interval of 0.53 to 2.69, which crosses one — so the increase in events does not automatically translate into a confirmed increase in deaths. The second brake matters more: an odds ratio describes groups, not a person. It is an argument for having your risk factors checked and followed, not an argument for alarm.
Sleep: obstructive sleep apnoea
The guideline notes that women with the condition have a significantly higher prevalence of obstructive sleep apnoea than women without it, independent of BMI (1.10.1), and recommends assessing for symptoms and screening with validated tools or referring for assessment where they are present (1.10.2). Loud snoring, witnessed pauses in breathing, and daytime sleepiness despite adequate hours in bed are all worth reporting to a doctor rather than tolerating.
The endometrium: the real risk, at its real size
Absent or widely spaced cycles mean longer oestrogen exposure without the usual cyclical balance, which is why the guideline states that premenopausal women with the condition "have markedly higher risk of developing endometrial hyperplasia and endometrial cancer" (1.11.1). It immediately balances that in the following point: women should be informed of the risk "acknowledging that the overall chance of developing endometrial cancer is low, therefore routine screening is not recommended" (1.11.2). The practical meaning is that restoring some regularity to the cycle is a medical goal in its own right — not a cosmetic one, and not only a fertility one.
Mental health and eating disorders
The guideline states that clinicians should screen for depression in all adults and adolescents with the condition using regionally validated tools (2.2.1), and likewise for anxiety (2.2.2) — both graded on high-quality evidence. It adds a point worth pausing on: "Eating disorders and disordered eating should be considered in PCOS, regardless of weight, especially in the context of weight management and lifestyle interventions" (2.5.1). The psychological side is not a footnote to the condition; it is a written item of care.
Is there a "PCOS diet"?
The short and honest answer is no. The international guideline states in recommendation 3.3.1 that "there is no evidence to support any 1 type of diet composition over another for anthropometric, metabolic, hormonal, reproductive, or psychological outcomes", and continues in 3.3.2 that any diet composition consistent with population guidelines for healthy eating will have health benefits, tailored to each woman's preferences and circumstances.
This is one of the most useful sentences in the entire document, because it releases you from hunting for the "correct" diet — gluten-free, low-carb, ketogenic, or whatever the label of the season happens to be — and puts the question back where it belongs: which pattern can you actually sustain? Sustainability is the variable. The headline is not.
Movement, by contrast, comes with a number
Lifestyle intervention is recommended for all women with the condition (3.1.1), and for adults aged 18 to 64 the dose is specified (3.4.3):
- 150 to 300 minutes per week of moderate-intensity activity, or 75 to 150 minutes of vigorous-intensity aerobic activity.
- Plus muscle-strengthening activities on two non-consecutive days per week.
Note that muscle strengthening is not an optional fitness add-on; it is part of the prescription itself. We devoted a full article to that point, on muscle and blood sugar, if you want to go deeper.
And weight is not an accusation
The guideline reminds clinicians to be "aware of weight stigma when discussing lifestyle management" (3.1.7). The condition is not the result of personal neglect, and it occurs in women of every body size — many lean women have it. The purpose of any change to how you eat or move is to improve symptoms and markers, not to hold anyone accountable for their shape.
Medication: why isn't there one drug for everyone?
Because there is not one goal. A woman who wants regular cycles and control of acne and unwanted hair is not in the same position as one planning a pregnancy this year, nor as one whose doctor is concerned about her metabolic markers. The latest guideline update therefore orders the options by goal:
- Cycle regularity and androgen symptoms: combined oral contraceptive pills are first-line pharmacological treatment, with no specific preparation recommended, and lower-dose formulations preferred.
- Metabolic features: metformin is recommended primarily for metabolic features, and has greater efficacy than inositol.
- Inositol: despite its popularity as a supplement, the guideline concludes that it offers limited clinical benefits — a fact worth stating plainly to anyone paying for it every month.
- Fertility: letrozole is first-line pharmacological therapy for ovulation induction, with clomiphene and others as second-line.
- Anti-obesity medications and metabolic surgery: may be considered based on general population guidelines, balancing potential benefits against side effects.
- In pregnancy: metformin is not routinely recommended for pregnant women with the condition, and an OGTT should be considered when planning pregnancy and again at 24 to 28 weeks of gestation (1.9.11).
These are names of treatments, not prescriptions: each has its own indications, contraindications and side effects, and the decision is a strictly medical one.
The condition in Saudi Arabia: the gap is not awareness
The World Health Organization estimates that the condition affects 10 to 13% of women globally, and that up to 70% of affected women are undiagnosed. More relevant locally, the international guideline states in recommendation 1.6.2 that prevalence is broadly similar across world regions but "may be higher in South East Asian and Eastern Mediterranean regions" — the region Saudi Arabia sits in.
In a cross-sectional survey of 408 women in the Eastern Province published in Frontiers in Reproductive Health in 2026, symptom-based prevalence was 19.9% while 16.7% reported a formal diagnosis, and 83.1% said they had heard of the condition. Read those numbers together and the message is clear: awareness of the name is high; the gap is in diagnosis and follow-up. The distance between "I've heard of it" and "I've been assessed for it" is a clinic appointment and a glucose test.
When should you see a doctor?
See your doctor — a gynaecologist or an endocrinologist — if you notice any of the following, and especially if two of them occur together:
- Irregular, widely spaced or absent periods over several months.
- Excess facial or body hair, treatment-resistant acne, or male-pattern hair thinning.
- Difficulty conceiving after regular attempts.
- An existing diagnosis without any assessment of your glycaemic status or blood pressure — ask for it.
- Loud snoring or heavy daytime sleepiness, or persistent symptoms of depression or anxiety.
⚠️ To repeat: all of the above is general education. Do not start or stop any medication or supplement on the basis of an article, and discuss any major dietary change with your doctor if you are pregnant, breastfeeding, or taking long-term medication.
Where does Bakery 8 stand in all this?
No bread treats this condition. We say it plainly because the international guideline itself — as you read above — says no single diet composition outperforms another here, and any product promising you otherwise is selling a promise rather than a treatment. The dietary decision belongs to you and your doctor.
What we can offer is one honest thing: if the pattern you and your doctor settled on is lower in carbohydrate and free of added sugar, the hard part is not knowing it — it is sustaining it through an ordinary, busy day, and sustainability is the only variable that genuinely matters. That is why at Bakery 8 (مخبز ثمانية) in Riyadh, Saudi Arabia, we make almond-flour, no-added-sugar alternatives: samoli bread and cloud bread in place of white bread at an ordinary meal, keto granola for a fast breakfast, and crackers for when you need something light between meals. Tools for a pattern you chose — not a treatment, and not a substitute for a doctor's appointment.
Frequently asked questions
Does the change to PMOS mean my previous diagnosis is no longer valid?
No. The name change does not alter the diagnostic criteria or the treatment plan, and your existing diagnosis stands exactly as it was. The transition is gradual over roughly three years and completes with the 2028 update of the international guideline, so you will keep seeing the old name in your medical file and insurance paperwork during that period.
Can I have the condition even though my ultrasound is normal?
Yes. The international guideline states that an ultrasound is not necessary for diagnosis when irregular cycles and hyperandrogenism are both present, because those two criteria suffice. Conversely, multiple follicles on an ultrasound alone do not confirm the condition, since that appearance also occurs in entirely healthy women.
Which test should I ask for?
The guideline recommends assessing glycaemic status at diagnosis in everyone, and considers the 75-g oral glucose tolerance test the most accurate, regardless of weight or BMI, repeated every one to three years. By contrast, clinically available insulin assays are not recommended in routine care because their clinical relevance is limited.
Are lean women affected too?
Yes, and the condition occurs in women of every body size. That is precisely why the oral glucose tolerance test recommendation is worded "regardless of BMI", and why the guideline warns clinicians about weight stigma. A normal weight is not a reason to delay testing or to dismiss the diagnosis.
Is inositol worth taking?
The latest guideline update concludes that inositol offers limited clinical benefits in this condition, and that metformin has greater efficacy for metabolic features. That is not a prohibition, but it does mean weighing what you spend on it against what it actually delivers, and discussing the alternatives with your doctor.
The bottom line
The new name is not an administrative detail; it is a correction to the compass of care. The condition is wider than the ovary, the ultrasound is not the hero of the story, the test worth asking for is a glucose assessment rather than an insulin level, and there is no magic diet — only a pattern you can sustain. Start with an appointment and one question: "has my glycaemic status and blood pressure been assessed?" And once you and your doctor have settled on a lower-carbohydrate pattern, Bakery 8 is here to make staying on it easier — healthy and delicious.
References
- Teede HJ, Bahri Khomami M, Piltonen T, Dokras A, et al. — "Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process", The Lancet, 13 May 2026.
- Monash University — media release: "Polyendocrine Metabolic Ovarian Syndrome: New name to improve diagnosis and care of condition affecting 170 million women worldwide", 2026.
- Monash Centre for Health Research and Implementation — "International Evidence-based Guideline for the assessment and management of PMOS" (updated edition), June 2026.
- Teede HJ et al. — "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome", The Journal of Clinical Endocrinology & Metabolism, Volume 108, Issue 10, 2023.
- Teede HJ et al. — the same recommendations in Human Reproduction, Volume 38, Issue 9, 2023.
- World Health Organization (WHO) — fact sheet: "Polycystic ovary syndrome".
- Journal of the American Heart Association — "2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights From a Systematic Review and Meta-Analysis on Elevated Clinical Cardiovascular Disease in Polycystic Ovary Syndrome", 2024.
- Cleveland Clinic — "Polycystic Ovary Syndrome (PCOS)".
- Mayo Clinic — "Polycystic ovary syndrome (PCOS): Symptoms and causes".
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH) — "What causes PCOS?".
- Yale Medicine — "PCOS Is Renamed PMOS: What You Need to Know", 2026.
- Nature Metabolism — "Polyendocrine metabolic ovarian syndrome — a new name for an old problem", 2026.
- Frontiers in Reproductive Health — "Prevalence of polycystic ovary syndrome and determinants of knowledge among women in the eastern province Saudi Arabia", 2026.
Related keywords: PCOS, polycystic ovary syndrome, PMOS, polyendocrine metabolic ovarian syndrome, PCOS new name, PCOS symptoms, PCOS diagnosis, PCOS insulin resistance, oral glucose tolerance test, PCOS diet, PCOS and pregnancy, PCOS in Saudi Arabia.